Introduction

Definition of Endocardial Fibroelastosis (EFE)

Endocardial Fibroelastosis (EFE) is a rare cardiac condition characterized by abnormal thickening of the endocardium, the inner lining of the heart, due to excessive deposition of fibrous and elastic tissue. Mostly affecting the left ventricle, this abnormal thickness disrupts regular cardiac function.

Pathophysiology overview

This type of restrictive cardiomyopathy results from the thicker endocardial layer making the ventricular wall less flexible and more rigid. This causes the heart to have trouble filling during diastole and issues with contraction, which ultimately results in heart failure. EFE may occur as a primary (idiopathic) disorder or as a secondary disorder as a result of autoimmune reactions, viral infections, or congenital heart disease.

Importance of medical management

Preventing the course of the illness, improving cardiac output (CO), and controlling symptoms all depend on early and efficient medical care. In the early or acute phases, drugs like diuretics and inotropes are essential for stabilizing the patient, even if some patients may eventually need surgery or a heart transplant .¹

Clinical presentation and diagnosis

Common symptoms

While rare adult cases of endocardial fibroelastosis (EFE) have been documented, the condition usually manifests in newborns and young children. Common symptoms are primarily associated with heart failure because of impaired cardiac function, these include:

• Failure to thrive (poor weight gain or growth)
• Rapid breathing (tachypnea)
• Shortness of breath (especially during feeding or activity)
• Fatigue and lethargy
• Sweating during feeds
• Enlarged liver (hepatomegaly)
• Pale or bluish skin in severe cases
• Heart murmur or arrhythmias

In older children, symptoms may also include exercise intolerance or chest discomfort.

Diagnostic Tools

Echocardiography (Echo)

• Ultrasound of the heart used as the primary tool for diagnosis
• EFE manifests as a thickened endocardium, enlarged heart chambers, and reduced ventricular function

Cardiac magnetic resonance imaging (cMRI)

• Provides detailed images of heart tissue
• Can confirm fibrosis and elastosis in the endocardium

Electrocardiogram (ECG)

• A reading of the electrical activity of the heart
• May reveal arrhythmias (abnormalities in the heart’s rhythm), conduction abnormalities, or signs of left ventricular hypertrophy (LVH)

Chest x-ray

• Can show cardiomegaly (enlarged heart) and pulmonary edema (congestion caused by fluid buildup in the lungs)

• Endomyocardial biopsy is a seldom-employed invasive test involving the extraction of a piece of cardiac tissue used when diagnosis is uncertain
• Confirms the presence of fibrous and elastic tissue histologically (under a microscope)²

Goals of medical management

While taking into account long-term possibilities like surgery or transplantation if necessary, the main goals of medical treatment for endocardial fibroelastosis (EFE) are to maintain heart function, alleviate symptoms, and prevent further progression of the condition.

Improve cardiac output

• In EFE, the ventricular wall becomes rigid, making it difficult for the heart to pump blood effectively
• Drugs (such as inotropes) are used to increase forward blood flow and the heart's contractility

Reduce fluid overload

• EFE frequently causes fluid accumulation in bodily tissues and lungs
• Diuretics such as furosemide aid the body in excreting extra fluid, which helps lessen associated symptoms including breathing problems and puffiness

Manage symptoms of heart failure

Medications aim to:

• Decrease breathlessness
• Reduce fatigue
• Improve feeding in infants
• Enhance quality of life

Stabilize for further interventions

Medical therapy is often a bridge to more definitive treatment:

• Surgical correction may be applicable in the presence of an underlying structural heart defect
• Heart transplantation in advanced or treatment-unresponsive cases

Support growth and development

Another primary treatment objective is to support weight growth, maintain nutritional status, and promote normal development despite cardiac limitations, particularly in infants.³

Diuretics in endocardial fibroelastosis (EFE)

A key component of the first line of medical treatment for EFE is diuretics. The symptoms of heart failure are largely caused by fluid overload, which they assist to alleviate.

Role of diuretics

Left ventricular dysfunction, which is frequently brought on by EFE, results in blood backing up into the lungs (pulmonary congestion) and the rest of the body (systemic congestion).

Diuretics work on the kidneys to increase urine output, this aids symptoms of EFE by:

• lowering the preload, or volume that enters the heart
• Improving symptoms such liver congestion, edema, and shortness of breath (dyspnea)
• Enhancing general comfort and tolerance to food, particularly in young children

Commonly used diuretics

Monitoring and side effects

Throughout treatment, monitoring of levels of various biomarkers (intrinsic molecules the levels of which can reflect on the state of disease and treatment progression) and other parameters like weight by a medical professional is essential.

Monitoring parameters

• Electrolytes (especially potassium and sodium)
• Kidney function (creatinine, BUN)
• Hydration status
• Weight (for tracking fluid loss/gain)

Potential side effects of treatment

• Electrolyte imbalance (hypokalemia, hyponatremia)
• Dehydration
• Hypotension (low blood pressure)
• Ototoxicity (rare, with high-dose furosemide)⁴

Inotropes in endocardial fibroelastosis (EFE)

A class of drugs called inotropes controls the power of contraction of the heart, ‘positive inotropes’ make the heart beat more forcefully. Particularly during acute decompensation (acute heart failure), inotropes are essential for maintaining cardiac output in EFE, when the heart's capacity to beat is hindered by stiff and swollen walls.

Role of inotropes

• Enhance myocardial contractility to improve forward blood flow
• Temporarily support circulation during acute heart failure episodes
• Serve as a bridge to more definitive treatment, such as surgery or transplantation

Commonly used inotropic agents

Monitoring and side effects

Monitoring parameters

• Heart rate and rhythm (risk of arrhythmias)
• Blood pressure
• Perfusion parameters (urine output, capillary refill)
• Electrolytes and renal function

Potential side effects

• Arrhythmias
• Tachycardia (increased heart rate >100bpm at rest)
• An abnormally low or high blood pressure (hypotension or hypertension)
• Tolerance with prolonged use (especially with dobutamine)⁵

Beyond diuretics and inotropes

In order to enhance treatment outcomes and quality of life, long-term care of EFE often involves additional drugs and supportive therapies beyond the use of diuretics and inotropes.

Afterload reducers

These drugs help the heart pump more efficiently by reducing resistance (afterload) against which the heart must contract. Depending on the specific receptor that these inhibit/block, they may be suited to different patients or disease pathologies.

ACE inhibitors (e.g., enalapril, captopril)

• Lower systemic vascular resistance (SVR)
• Reduce workload on the heart
• May slow disease progression by modulating the renin-angiotensin-aldosterone system (RAAS)

Angiotensin II receptor blockers (ARBs)

• Alternative for patients who cannot tolerate ACE inhibitors (for instance due to cough or angioedema)

Beta-blockers (e.g., carvedilol, metoprolol)

• Used cautiously in stable, chronic cases
• Help reduce heart rate and oxygen demand
• May improve long-term cardiac remodeling in selected patients

Anticoagulation

Patients with ventricular thrombus, atrial fibrillation, or significantly diminished cardiac function may benefit from treatment with anticoagulants. The usage of warfarin or heparin depends on the patient's age and health. In extremely young children, it is typically advised to avoid using ‘newer’, more targeted, oral anticoagulants due to lack of regulations and risk of bleeding.⁶

Nutritional support

Feeding and weight gain are common challenges for infants with EFE. Adding more calories (via feeding tubes or high-energy formula). A nutritionist or pediatric dietitian's close supervision is crucial.

Immunosuppressive or antiviral therapy

Used only in selected cases with suspected or confirmed viral myocarditis (infection of the heart muscle by a virus such as Coxsackie B) and autoimmune involvement.
Examples include:

• Intravenous immunoglobulin (IVIG)
• Steroids
• Antiviral agents (if a specific viral infection is identified)

Other supportive measures

• Oxygen therapy in cases of hypoxia
• Electrolyte replacement if imbalances as a result of diuretics use occur
• Monitoring for arrhythmias and initiating anti-arrhythmic therapy if needed

Heart transplantation

Heart transplant is the definitive treatment (last resort which will provide the best possible outcome of eliminating disease) for patients with advanced EFE and irreversible heart failure. Transplantation is a highly invasive and traumatic procedure, especially in pediatric cases where the age of both the donor and patient need to be accounted for. However, it may be necessary to consider as a last-line treatment in some cases.⁷

When to consider transplant

• Persistent symptoms despite optimal medical therapy (OMT)
• Recurrent hospitalizations for heart failure
• Progressive ventricular dysfunction
• Failure to thrive (FTT) or poor quality of life as a result of insufficient weight gain/growth

Long-term monitoring

Long-term care of EFE primarily consists of continuing observation, modifying therapy, and promoting development, particularly in young children.

Follow-up care

Evaluation of the function of the heart and adapting prescriptions according to test results and symptoms, keeping an eye out for issues including worsening heart failure, arrhythmias, or malfunctioning valves.

Cardiac imaging

• Echocardiograms every few months or as symptoms change
• Cardiac MRI as needed for detailed tissue assessment

Electrocardiography (ECG) and holter monitoring

• To detect arrhythmias or conduction problems

Lab tests

• Kidney function, electrolytes, and drug levels
• BNP/NT-proBNP may help assess heart failure severity

 Growth and nutrition monitoring

• Especially important in infants and young children to avoid FTT
• Diet adjustments or feeding support as needed

Medication adjustment

May involve:

• Tapering or intensifying use of diuretics, inotropes, or afterload reducers based on stability of the patient
• Introduction or removal of beta-blockers, anticoagulants, or supplements as needed.⁸

Summary

The rare yet dangerous heart disorder known as endocardial fibroelastosis (EFE) primarily affects newborns and young children. Because of its impacts on the endocardium, causing it to become thickened and rigid, EFE results in poor ventricular compliance and contractility, which in turn causes heart failure symptoms.

Medical management is the first line of therapy and aims to:

• Relieve fluid overload using diuretics
• Improve heart function with inotropes
• Support long-term heart performance with afterload reducers and other medications

Beyond standard therapy, patients may require advanced interventions such as heart transplantation in refractory or severe cases.

Regular heart monitoring, modifications of drug admission, dietary assistance, and attending to a patient’s psychological needs are all part of long-term care. Though the prognosis varies depending on severity and response to therapy, results can be enhanced with early identification, skilled medical management, and prompt escalation of care as necessary. For kids with EFE to have the highest quality of life possible, multidisciplinary treatment is crucial.